Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	956,826	401,346	2,077,519	1,352,734
Depreciation	436	502	1,308	1,507
Research and development (including stock-based compensation (Note 8))	680,436	85,802	1,125,937	324,127
Total operating expenses	1,637,698	487,650	3,204,764	1,678,368
Loss from operations	(1,637,698)	(487,650)	(3,204,764)	(1,678,368)
Other expense (income):
Gain on extinguishment of liabilities (Note 5)			(718,580)
Conversion inducement	8,000		8,000
Interest expense, net	84,714	94,640	276,815	281,969
Total other expense (income)	92,714	94,640	(433,765)	281,969
Net loss	(1,730,412)	(582,290)	(2,770,999)	(1,960,337)
Net loss attributable to the noncontrolling interest	1,472	508	2,486	1,904
Net loss applicable to Bion's common stockholders	$ (1,728,940)	$ (581,782)	$ (2,768,513)	$ (1,958,433)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.07)	$ (0.02)	$ (0.11)	$ (0.08)
Weighted-average number of common shares outstanding: Basic and diluted (in shares)	24,465,814	23,348,981	24,253,807	23,407,626